JP2013513609A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013513609A5 JP2013513609A5 JP2012543221A JP2012543221A JP2013513609A5 JP 2013513609 A5 JP2013513609 A5 JP 2013513609A5 JP 2012543221 A JP2012543221 A JP 2012543221A JP 2012543221 A JP2012543221 A JP 2012543221A JP 2013513609 A5 JP2013513609 A5 JP 2013513609A5
- Authority
- JP
- Japan
- Prior art keywords
- photodynamic therapy
- nanoparticles
- group
- diseases
- photosensitizer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000002105 nanoparticle Substances 0.000 claims 9
- 238000002428 photodynamic therapy Methods 0.000 claims 9
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 239000003504 photosensitizing agent Substances 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 4
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 239000003381 stabilizer Substances 0.000 claims 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims 3
- 238000002360 preparation method Methods 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 102000008100 Human Serum Albumin Human genes 0.000 claims 2
- 108091006905 Human Serum Albumin Proteins 0.000 claims 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 238000004807 desolvation Methods 0.000 claims 2
- 239000002245 particle Substances 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 239000000243 solution Substances 0.000 claims 2
- 230000000087 stabilizing effect Effects 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 claims 1
- HORNXRXVQWOLPJ-UHFFFAOYSA-N 3-chlorophenol Chemical compound OC1=CC=CC(Cl)=C1 HORNXRXVQWOLPJ-UHFFFAOYSA-N 0.000 claims 1
- 241000894006 Bacteria Species 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- LYPFDBRUNKHDGX-SOGSVHMOSA-N N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 Chemical group N1C2=CC=C1\C(=C1\C=CC(=N1)\C(=C1\C=C/C(/N1)=C(/C1=N/C(/CC1)=C2/C1=CC(O)=CC=C1)C1=CC(O)=CC=C1)\C1=CC(O)=CC=C1)C1=CC(O)=CC=C1 LYPFDBRUNKHDGX-SOGSVHMOSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108010038807 Oligopeptides Proteins 0.000 claims 1
- 102000015636 Oligopeptides Human genes 0.000 claims 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims 1
- 229930006000 Sucrose Natural products 0.000 claims 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 claims 1
- 208000012931 Urologic disease Diseases 0.000 claims 1
- 230000000274 adsorptive effect Effects 0.000 claims 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 claims 1
- 239000007900 aqueous suspension Substances 0.000 claims 1
- 150000004036 bacteriochlorins Chemical class 0.000 claims 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims 1
- 125000000837 carbohydrate group Chemical group 0.000 claims 1
- SURLGNKAQXKNSP-DBLYXWCISA-N chlorin Chemical compound C\1=C/2\N/C(=C\C3=N/C(=C\C=4NC(/C=C\5/C=CC/1=N/5)=CC=4)/C=C3)/CC\2 SURLGNKAQXKNSP-DBLYXWCISA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000001914 filtration Methods 0.000 claims 1
- 238000007710 freezing Methods 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 125000003827 glycol group Chemical group 0.000 claims 1
- 238000010438 heat treatment Methods 0.000 claims 1
- 230000002209 hydrophobic effect Effects 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 239000003960 organic solvent Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 150000004032 porphyrins Chemical class 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 208000017520 skin disease Diseases 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 239000005720 sucrose Substances 0.000 claims 1
- 229960002197 temoporfin Drugs 0.000 claims 1
- 208000014001 urinary system disease Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28590209P | 2009-12-11 | 2009-12-11 | |
| US61/285,902 | 2009-12-11 | ||
| US12/941,350 US9211283B2 (en) | 2009-12-11 | 2010-11-08 | Nanoparticle carrier systems based on human serum albumin for photodynamic therapy |
| US12/941,350 | 2010-11-08 | ||
| PCT/US2010/059364 WO2011071968A2 (en) | 2009-12-11 | 2010-12-08 | Nanoparticle carrier systems based on human serum albumin for photodynamic therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013513609A JP2013513609A (ja) | 2013-04-22 |
| JP2013513609A5 true JP2013513609A5 (enExample) | 2014-08-14 |
| JP5972171B2 JP5972171B2 (ja) | 2016-08-17 |
Family
ID=44143223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012543221A Expired - Fee Related JP5972171B2 (ja) | 2009-12-11 | 2010-12-08 | 光力学的療法のためのヒト血清アルブミンをベースにしたナノ粒子キャリアシステム |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US9211283B2 (enExample) |
| EP (1) | EP2509620A4 (enExample) |
| JP (1) | JP5972171B2 (enExample) |
| CN (1) | CN102740875A (enExample) |
| BR (1) | BR112012013952A2 (enExample) |
| CA (1) | CA2784001C (enExample) |
| WO (1) | WO2011071968A2 (enExample) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2591803A1 (de) * | 2011-11-09 | 2013-05-15 | APOCARE Pharma GmbH | Zusammensetzung für die photodynamische Diagnostik und Therapie von Tumoren |
| CN103169968B (zh) * | 2013-03-12 | 2014-11-26 | 中国科学院理化技术研究所 | 一种基于白蛋白的疏水二氢卟吩光敏剂纳米药物制剂、制备方法及其应用 |
| KR101329646B1 (ko) | 2013-05-02 | 2013-11-14 | 주식회사 지니스 | 표적지향증폭형 항암나노입자 및 이의 제조방법 |
| US10456375B2 (en) | 2014-09-30 | 2019-10-29 | Biolitec Unternehmensbeteiligungs Ii Ag | Specifically meso-substituted porphyrins and chlorins for photodynamic therapy |
| CN104587466B (zh) * | 2014-12-15 | 2017-11-21 | 苏州大学 | 蛋白‑聚吡咯复合物及蛋白‑聚吡咯复合物衍生物的制备方法与应用 |
| ES3011714T3 (en) | 2016-02-26 | 2025-04-08 | Biolitec Holding Gmbh & Co Kg | Conjugates of porphyrinoid photosensitizers and glycerol-based polymers for photodynamic therapy |
| DE102016125666A1 (de) * | 2016-12-23 | 2018-06-28 | Michael Denck | HSA-Galenik |
| JP7110360B2 (ja) | 2017-10-09 | 2022-08-01 | テルモ ビーシーティー バイオテクノロジーズ，エルエルシー | 凍結乾燥方法 |
| EP3894421A1 (en) | 2018-12-10 | 2021-10-20 | Universität Hamburg | Specifically glyco-substituted porphyrins and chlorins for photodynamic therapy |
| CN113597532B (zh) | 2019-03-14 | 2023-02-17 | 泰尔茂比司特生物技术有限公司 | 冻干容器填充固定装置、系统及使用方法 |
| CN110251672B (zh) * | 2019-06-18 | 2022-04-01 | 深圳大学 | 一种纳米诊疗剂及其制备方法与应用 |
| CN111110861B (zh) * | 2020-02-23 | 2023-08-25 | 上海交通大学医学院附属瑞金医院 | 一种基于人血清白蛋白的载药颗粒及其制备方法 |
| CN112972676B (zh) * | 2020-08-17 | 2024-09-24 | 滨州医学院 | HSA-Biotin-DDA-TCPP分子的合成及其作为光动力治疗剂及纳米药的应用 |
| WO2022074014A1 (en) * | 2020-10-05 | 2022-04-14 | Biolitec Unternehmensbeteiligungs Ii Ag | Tetrapyrrole-based compounds and their formulations for anti-microbial therapy |
| CN113855645B (zh) * | 2021-09-13 | 2024-02-02 | 苏州大学 | 一种基于功能化蛋白质纳米粒的核壳型组装体及其制备方法与应用 |
| WO2023039691A1 (zh) * | 2021-09-17 | 2023-03-23 | 苏州大学 | 一种基于功能化蛋白质纳米粒的核壳型组装体及其制备方法与应用 |
| JP2024534479A (ja) * | 2021-09-17 | 2024-09-20 | ユニバーシティ オブ メリーランド， カレッジ パーク | 非晶質光増感性粒子、その調製方法、及びその使用方法 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8805849D0 (en) | 1988-03-11 | 1988-04-13 | Efamol Holdings | Porphyrins & cancer treatment |
| US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
| GB9420355D0 (en) * | 1994-10-10 | 1994-11-23 | Univ Nottingham | Preparation of protein microspheres, films and coatings |
| US5648485A (en) | 1994-10-26 | 1997-07-15 | University Of British Columbia | β, β-dihydroxy meso-substituted chlorins, isobacteriochlorins, and bacteriochlorins |
| US6649192B2 (en) * | 1996-07-29 | 2003-11-18 | Universidade De Santiago De Compostela | Application of nanoparticles based on hydrophilic polymers as pharmaceutical forms |
| US6620929B1 (en) | 1999-04-14 | 2003-09-16 | University Of British Columbia | 1,3-Dipolar cycloadditions to polypyrrolic macrocycles |
| ATE347886T1 (de) | 1999-09-23 | 2007-01-15 | Dabur Pharma Ltd | Arzneizubereitungen enthaltend paclitaxel eingeschlossen in nanopartikeln von polymerischen mizellen |
| JP2005502618A (ja) * | 2001-06-04 | 2005-01-27 | ザ・ジェネラル・ホスピタル・コーポレイション | 光力学的化合物を用いて脆弱なプラークを検出および治療する方法 |
| US7455858B2 (en) | 2002-05-16 | 2008-11-25 | Qlt Inc. | Compositions and methods for delivery of photosensitive drugs |
| US8709449B2 (en) * | 2004-02-12 | 2014-04-29 | Biolitec Pharma Marketing Ltd | Methods and compositions for improving photodynamic therapy through administration of lipids |
| DE102004011776A1 (de) * | 2004-03-09 | 2005-11-03 | Lts Lohmann Therapie-Systeme Ag | Trägersystem in Form von Nanopartikeln auf Proteinbasis zur zellspezifischen Anreicherung von pharmazeutisch aktiven Wirkstoffen |
| JP2006056807A (ja) * | 2004-08-18 | 2006-03-02 | Konica Minolta Medical & Graphic Inc | 光線力学療法製剤 |
| US20070218049A1 (en) * | 2006-02-02 | 2007-09-20 | Wei Chen | Nanoparticle based photodynamic therapy and methods of making and using same |
| US20090304803A1 (en) * | 2005-06-06 | 2009-12-10 | The General Hospital Corporation | Compositions and methods relating to target-specific photodynamic therapy |
| CN101485629B (zh) * | 2008-01-16 | 2013-01-23 | 沈阳药科大学 | 一种给药系统及其制备方法 |
| TW200942233A (en) * | 2008-04-10 | 2009-10-16 | Abraxis Bioscience Llc | Compositions of hydrophobic taxane derivatives and uses thereof |
| US8815931B2 (en) * | 2009-04-28 | 2014-08-26 | Biolitec Pharma Marketing Ltd | Oral formulations for tetrapyrrole derivatives |
| CN102414556B (zh) * | 2009-04-30 | 2015-09-02 | 赛默科技便携式分析仪器有限公司 | 利用具有不同检验体积的xrf分析对关注元素定位 |
| US20110275686A1 (en) * | 2009-12-11 | 2011-11-10 | Biolitec, Inc. | Nanoparticle carrier systems based on poly(dl-lactic-co-glycolic acid) (plga) for photodynamic therapy (pdt) |
-
2010
- 2010-11-08 US US12/941,350 patent/US9211283B2/en active Active
- 2010-12-08 JP JP2012543221A patent/JP5972171B2/ja not_active Expired - Fee Related
- 2010-12-08 WO PCT/US2010/059364 patent/WO2011071968A2/en not_active Ceased
- 2010-12-08 EP EP10836582.6A patent/EP2509620A4/en active Pending
- 2010-12-08 CA CA2784001A patent/CA2784001C/en not_active Expired - Fee Related
- 2010-12-08 BR BR112012013952-5A patent/BR112012013952A2/en not_active IP Right Cessation
- 2010-12-08 CN CN2010800629189A patent/CN102740875A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013513609A5 (enExample) | ||
| JP2013513610A5 (enExample) | ||
| Zhu et al. | Pillararene-based supramolecular systems for theranostics and bioapplications | |
| Kim et al. | Ceria‐based therapeutic antioxidants for biomedical applications | |
| JP5972171B2 (ja) | 光力学的療法のためのヒト血清アルブミンをベースにしたナノ粒子キャリアシステム | |
| JP5868869B2 (ja) | 光力学的療法のための乳酸・グリコール酸共重合体をベースにしたナノ粒子キャリアシステム | |
| Aktaş et al. | Development and brain delivery of chitosan− PEG nanoparticles functionalized with the monoclonal antibody OX26 | |
| Sarparanta et al. | Intravenous delivery of hydrophobin-functionalized porous silicon nanoparticles: stability, plasma protein adsorption and biodistribution | |
| CA2957940C (en) | Dendrimer compositions and use in treatment of neurological and cns disorders | |
| Yadav et al. | Chitosan-based nanoformulations: preclinical investigations, theranostic advancements, and clinical trial prospects for targeting diverse pathologies | |
| CN105749280A (zh) | 一种协同化疗与光动力治疗的肿瘤靶向纳米给药系统的制备及应用 | |
| KR102640250B1 (ko) | 암 및 안 질환의 치료를 위한 알부민 나노입자들 | |
| CN114209852B (zh) | 一种声响应型载药棒状介孔硅及其制备方法与应用 | |
| Li et al. | Multifunctional cell membranes-based nano-carriers for targeted therapies: a review of recent trends and future perspective | |
| Wang et al. | Peptide‐based supramolecular therapeutics for fighting major diseases | |
| CN109806394B (zh) | 一种介孔二氧化硅药物递送系统及其应用 | |
| CN105288646A (zh) | 一种光敏剂磷脂化合物、其药物组合物及应用 | |
| Cui et al. | Pulmonary delivery of Recombinant human bleomycin hydrolase using Mannose-Modified hierarchically porous UiO-66 for preventing bleomycin-Induced pulmonary fibrosis | |
| CN106177972B (zh) | 一种白蛋白与蒽环霉素类抗癌药的分子复合物及其制备方法 | |
| WO2020143688A1 (zh) | 一种用于防治早期神经退行性疾病的鼻腔纳米自噬诱导剂及其制备方法 | |
| Singh et al. | The significance of nanomedicine in brain-targeted drug delivery: crossing blood-brain barriers | |
| CN114796514B (zh) | 水溶性正离子型超分子有机框架共价纳米仿生给药系统 | |
| ES2872223T3 (es) | Nuevo procedimiento para la preparación de forskolina soluble en agua | |
| Li et al. | Research Progress on the nano-delivery systems of antitumor drugs | |
| Zou et al. | Nanoscale glutathione-functionalized bone marrow mesenchymal stem cell-derived exosomes loaded with metformin for the treatment of spinal cord injury |